Barasertib (AZD1152-HQPA)

Catalog No.S1147 Synonyms: AZD2811, INH-34, Barasertib-HQPA , Defosbarasertib

For research use only.

Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Barasertib (AZD1152-HQPA) Chemical Structure

CAS No. 722544-51-6

Selleck's Barasertib (AZD1152-HQPA) has been cited by 105 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Other Aurora Kinase Products

Biological Activity

Description Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Targets
Aurora B [1]
(Cell-free assay)
0.37 nM
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP NV73T2xHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TncVAuPTByIH7N MXG0POKhcA>? Ml\CTWM2OD1{NTDuUS=> MnWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e2OVkoRjJ3Mke3OlU6RC:jPh?=
LNCaP NGXrVHdCeG:ydH;zbZMhSXO|YYm= M{LU[|AuPTByIH7N MYW0POKhcA>? M33zUolv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIghfGi{b4XnbEBk[XOyYYPlMVMhfXC{ZXf1cIF1cW:w NG\PVJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Y2QSd-MkWyO|c3PTl:L3G+
LNCaP NILiZVBHfW6ldHnvckBCe3OjeR?= NFn6N4w2OCCwTR?= MWm0PEBp MYDpcoR2[2W|IH3pZ5JwdnWlbHXpJJdqfGhiYX7leYdmdmmlIH3lZ4hidmm|bR?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{[1PUc,OjV{N{e2OVk9N2F-
Ramos M3XMd2Z2dmO2aX;uJGF{e2G7 NFGwRYg2ODBibl2= M2jlO|AuPzJiaB?= MVrpcohq[mm2czDBeZJwemFiQjDrbY5ie2V? NIrCVHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Daudi  NIfo[JRHfW6ldHnvckBCe3OjeR?= NWfrS4NyPTByIH7N NWDKe4VvOC15MjDo Mm\MbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn M4G1eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L540 NHXJZYNHfW6ldHnvckBCe3OjeR?= NHT4b4U2ODBibl2= M3q4bFAuPzJiaB?= M{TmVolvcGmkaYTzJGF2em:{YTDCJItqdmG|ZR?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
BJAJ NITo[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjnSIN[PTByIH7N MnjvNE04OiCq NEe3W3pqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 M37C[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Ramos Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITMTGs2ODBibl2= MYmwMVczKGh? M{TKZolvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= MmKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Raji NFW0OYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfIflM2ODBibl2= MnjJNE04OiCq NYPYXJd{cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> M2TkSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Daudi  M2LjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq5OVAxKG6P NIq3OmQxNTd{IHi= Mk\pbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
L428 MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;DO|UxOCCwTR?= NV7KTpBqOC15MjDo NVXPOmRXcW6qaXLpeJMh[2WubDDndo94fGh? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
KM-H2 M4jCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\seHI2ODBibl2= M{n0dFAuPzJiaB?= NGLUZWFqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NEHWbVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
HDLM-2 M1;VcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHZOVAxKG6P NYfQTHg2OC15MjDo NYjm[ZA6cW6qaXLpeJMh[2WubDDndo94fGh? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
L450 NUHyNHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WyRVUxOCCwTR?= NWXqUG9OOC15MjDo MUTpcohq[mm2czDj[YxtKGe{b4f0bC=> M1:0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
BJAJ MmTQRZBweHSxc3nzJGF{e2G7 MX:1NFAhdk1? M2TXSFAuPzJiaB?= MXHpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Ramos NUjJc3M6SXCxcITvd4l{KEG|c3H5 MWK1NFAhdk1? Ml;MNE04OiCq NFPITZFqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Raji M2C0O2Fxd3C2b4Ppd{BCe3OjeR?= M{O2SFUxOCCwTR?= NFfpUFYxNTd{IHi= M{TqTIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Daudi  NEH4VYNCeG:ydH;zbZMhSXO|YYm= MVm1NFAhdk1? M121T|AuPzJiaB?= MXrpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MnXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
L428 Ml2yRZBweHSxc3nzJGF{e2G7 MWG1NFAhdk1? NXKyeZptOC15MjDo M{\HRYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy M3vnc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
KM-H2 NFvrcnFCeG:ydH;zbZMhSXO|YYm= NF7ScGY2ODBibl2= MlHxNE04OiCq MVLpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NYHJbJFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
HDLM-2 NIjjUJhCeG:ydH;zbZMhSXO|YYm= NFHNflk2ODBibl2= NYG3fVlQOC15MjDo MXfpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NFXXNYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L450 M3;rO2Fxd3C2b4Ppd{BCe3OjeR?= NXzzSZNLPTByIH7N NXfuc2Y1OC15MjDo M2D5S4lv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
SW620 NW\BeJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTa[WRGSzVyPUGwxtEzNjFibl2= NEjl[HU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK0OVA6OCd-MkGyOFUxQTB:L3G+
HCT116 M{K3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwSWM2OD1zMdMxN{4{KG6P MkjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{NEWwPVAoRjJzMkS1NFkxRC:jPh?=
MDA-MB-435 NELHTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPyXoYxNTFyMECwJI5O MmDjNk02KGR? MYrEUXNQ NUDURWIyUUN3ME2xNlUhdk1? NGH4flI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-468 NHvldplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMVExODByIH7N MnG4Nk02KGR? MYjEUXNQ M4\OOmlEPTB;MUSgcm0> NWn3TGNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
MDA-MB-231 NVXWSpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvqTHJvOC1zMECwNEBvVQ>? M1jlT|IuPSCm NHf2U2pFVVOR M3PQTmlEPTB;MUC1JI5O MnHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzN{W5NlYoRjJyMUe1PVI3RC:jPh?=
BT474 NHLud4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXiwMVExODByIH7N M4\GTlIuPSCm MnrSSG1UVw>? NFLD[pVKSzVyPUigcm0> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-361 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkflNE0yODByMDDuUS=> M2DHOVIuPSCm M4TsbmROW09? NVLJNmxVUUN3ME23NEBvVQ>? NWfwRohkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
HER18 NILmfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Ox[FAuOTByMECgcm0> M4LZUlIuPSCm Mn\ySG1UVw>? MXfJR|UxRTJyIH7N NV;GdWMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
HER18 NW\rWJFISXCxcITvd4l{KEG|c3H5 NXfGW3lKOTByIH7N MUCwM|I1NzR6IHi= Mn;kSG1UVw>? MWrpcoR2[2W|IHHwc5B1d3OrczDhcoQhemWmdXPld{BkdG:wb3flcolkKHCxdHXueIlidA>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-231 NEC2bnNCeG:ydH;zbZMhSXO|YYm= M{DDV|ExPSCwTR?= NE[1PIcxNzJ2L{S4JIg> M1;sXmROW09? MXvpcoR2[2W|IHHwc5B1d3OrczDhcoQhemWmdXPld{BkdG:wb3flcolkKHCxdHXueIlidA>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
JHH-1 M4ri[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOwMlPjiJNzMECwxsBvVQ>? MkXsO|IhcA>? MnqySWM2OD1zNz60xtEyNjBibl2= M1T3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
JHH-2 NYr3UYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP4eo4xNjQkgKOxNFAxyqCwTR?= MonqO|IhcA>? M17SUmVEPTB;MkG4MlDDuTFyLkigcm0> NV7Ieo56RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
JHH-4 NIXOWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfvNE4{6oDVMUCwNOKhdk1? M1jDdFczKGh? MkfXSWM2OD1zNUWuOuKyOTZwODDuUS=> MnjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HuH-1 NYPiNGJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[wMlPjiJNzMECwxsBvVQ>? NXXlU2s3PzJiaB?= MXnFR|UxRTJ5LkRCtVUvOCCwTR?= MnLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HuH-6 M{LuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmwMlPjiJNzMECwxsBvVQ>? MWi3NkBp NVr3UIV1TUN3ME2zMlfDuTBwNjDuUS=> NYfHPXVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HuH-7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnyfWsxNjQkgKOxNFAxyqCwTR?= MUS3NkBp MkDKSWM2OD14LklCtVAvOyCwTR?= NU\FRYgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HLE MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnmNE4{6oDVMUCwNOKhdk1? MUW3NkBp NF30Vo5GSzVyPUS1MlnDuTZwNDDuUS=> NW\NNoNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HLF NUHTPVFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf4[HY6OC5|4pETNVAxOMLibl2= NEPsT|E4OiCq Moi2SWM2OD1zMk[uNeKyOTJwMjDuUS=> MkPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
PLC/PRF/5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnuNE4{6oDVMUCwNOKhdk1? MX63NkBp NFLCcZpGSzVyPUe2MlnDuTlwOTDuUS=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
SK-Hep1 M323Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD6NE4{6oDVMUCwNOKhdk1? M4[4S|czKGh? NI\nVoVGSzVyPUKxMlnDuTFwMjDuUS=> NIG1T2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
Hep3B NUnXeGVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fWXFAvO+LCk{GwNFDDqG6P MnvnO|IhcA>? MVjFR|UxRTdwNtMxNU4zKG6P Mo[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HepG2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\zWWQxNjQkgKOxNFAxyqCwTR?= NXu4SYZ4PzJiaB?= MnPuSWM2OD1zND63xtEyNjdibl2= NGrHNlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
Ramos M2L4cGFxd3C2b4Ppd{BCe3OjeR?= MoKyNlUwPTBxMUCwJI5O MVe0PEBp M2XXd4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> NIruS2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyN|E3QCd-MUm4NlMyPjh:L3G+
Daudi  M2rYeWFxd3C2b4Ppd{BCe3OjeR?= M2L5bVI2NzVyL{GwNEBvVQ>? NX64UYoxPDhiaB?= NXrUXGR1cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G|cHHz[UA{ NYC1W2EzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NlMyPjhpPkG5PFI{OTZ6PD;hQi=>
BALM-14 MXnBdI9xfG:|aYOgRZN{[Xl? M4O0SVEzNjVxMkWvOVAhdk1? NV7JfIo2PDhiaB?= M2r5bYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> NXXnNmNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NlMyPjhpPkG5PFI{OTZ6PD;hQi=>
BALM-27 NHjhT4hCeG:ydH;zbZMhSXO|YYm= M1XaWlEzNjVxMkWvOVAhdk1? NWHEXXhKPDhiaB?= MVzpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= NYXSPFFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NlMyPjhpPkG5PFI{OTZ6PD;hQi=>
NB4 M3vyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfxNE4xOS9yLkGvNUDPxE1? MlXuOFghcA>? Mk\jbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= M37ycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{[3OFg1Lz5zOEO2O|Q5PDxxYU6=
HeLa MkniSpVv[3Srb36gRZN{[Xl? NWHzZpZPOSC3TR?= NVLKT4dHOjRiaILz MmPwTY5pcWKrdHnvckBw\iCjdYLvdoEhSiCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0eIlv\w>? NHT6Rmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU1QSd-MkC2PFQ2PDl:L3G+
Assay
Methods Test Index PMID
Western blot AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN ; p53 / p21 / p-p38 / p38 26497213 24782314
Immunofluorescence p21 24782314
Growth inhibition assay Cell viability 26497213

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

7mg/mL

Chemical Information

Molecular Weight 507.56
Formula

C26H30FN7O3

CAS No. 722544-51-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02579226 Completed Drug: AZD2811 Advanced Solid Tumours AstraZeneca October 28 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

Answer:
S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Tags: buy Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) supplier | purchase Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) cost | Barasertib (AZD1152-HQPA) manufacturer | order Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) distributor